Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 18/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636731 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL7875034 | 0.89 | CYP2C9 (0.80) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL288500 | 0.85 | CYP3A4 (0.74) | CYP2C9CYP3A4CYP2C19BRAF | |
| SCHEMBL13961979 | 0.85 | CYP3A4 (0.74) | CYP2C9CYP3A4CYP2C19BRAF | |
| Hydrochloric Acid SCHEMBL27813044 | 0.84 | CYP3A4 (0.72) | CYP2C9CYP3A4CYP2C19BRAF | |
| SCHEMBL7869189 | 0.82 | CYP2C9 (0.70) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL24570795 | 0.81 | CYP2C19 (0.68) | CYP2C9CYP3A4CYP2C19BRAF | |
| SCHEMBL1437671 | 0.81 | CYP3A4 (0.68) | CYP2C9CYP3A4CYP2C19BRAF | |
| SCHEMBL1818143 | 0.81 | CYP2C9 (0.68) | CYP2C9CYP3A4CYP2C19CYP2D6BRAF | |
| SCHEMBL8222877 | 0.80 | CYP3A4 (0.67) | CYP2C9CYP3A4CYP2C19BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| EP-3746437-B1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| CN-117497847-A | Lithium ion battery electrolyte capable of improving first efficiency of battery and reducing direct-current internal resistance | 合肥国轩高科动力能源有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| CN-111788195-B | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210078995-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| WO-2009143024-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-08-07 | — | — | US | disclosed |
| WO-2008079909-A1 | PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | CYP2C9 2304/4885CYP3A4 3358/4885CYP2C19 2661/4885 |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | CYP2C9 2417/4885CYP3A4 3520/4885CYP2C19 2774/4885 |
| US-20210078995-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP3A4 971/4885CYP2C19 4255/4885 |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP3A4 971/4885CYP2C19 4255/4885 |
| US-20080188514-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP3A4 4658/4885CYP2C19 4579/4885 |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP3A4 971/4885CYP2C19 4255/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP3A4 971/4885CYP2C19 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.